Meet Our Team
Dr. Mark Atkinson is the American Diabetes Association Eminent Scholar for Diabetes Research. Dr. Atkinson has devoted more than 30 years to his research and to helping people affected by Type 1 diabetes around the world. He is an internationally recognized authority in the field and is the author of over 375 publications. The Atkinson Lab has particular interests in disease prediction and prevention, environmental factors, stem cells and pancreatic regeneration, and the identification of markers for tolerance and immunoregulation. »More
Dr. Todd Brusko and his staff of diabetes researchers at the University of Florida are dedicated to the development of safe and effective therapies to prevent and reverse Type 1 diabetes. His laboratory works in close collaboration with Michael Haller, M.D. and Desmond Schatz, M.D. to conduct mechanistic studies in ongoing clinical trials and generate novel avenues for therapeutic intervention. »More
Professor Martha Campbell-Thompson, D.V.M., Ph.D., earned her doctorate in veterinary medicine and veterinary physiology from the University of Florida. Dr. Campbell-Thompson has over 20 years experience in animal models of human disease with an emphasis on Type 1 diabetes. She is the primary administrator of the Pathology Core for UF’s innovative nPOD resource. In collaboration with the Atkinson Lab, Dr. Campbell-Thompson has become the lead pathologist for all rodent and human Type 1 diabetes studies. »More
Dr. Michael Clare-Salzler’s areas of clinical expertise lie in the diagnosis and management of Type 1 diabetes, autoimmune thyroid disease, management of thyroid nodules, fine aspiration of thyroid nodules and thyroid cancer. He is also well versed in other endocrine diseases including Cushing’s Disease, pituitary disease, pheochromocytoma, adrenal tumors and parathyroid diseases. Dr. Clare-Salzler is a member of the NIH funded International Multi-Center diabetes prevention trial, the Diabetes Prevention Trial for T1D (DPT-1). He is an investigator for diabetes screening programs at UF including the PANDA program. »More
Dr. Patrick Concannon’s areas of expertise include the role of genetics in Type 1 diabetes, breast cancer, malnutrition and radiation sensitivity. He previously served as the University of Virginia’s Center for Public Health Genomics and is a professor of biochemistry and molecular genetics, as well as a professor of hematology and oncology. With over 25 years of research work and supported by more than $12 million in grants from the National Institutes of Health, the Bill and Melinda Gates Foundation and the Juvenile Diabetes Research Foundation, Dr. Concannon’s work has led to more than 35 book chapters and 175 peer-reviewed papers in top journals, including Nature, the Journal of the American Medical Association, The New England Journal of Medicine and the Proceedings of the National Academy of Sciences. »More
Dr. Kenneth Cusi currently serves as Chief of the Adult Division of Endocrinology, Diabetes & Metabolism in the Department of Medicine at the University of Florida. He oversees all adult endocrinology/diabetes inpatient consult activities and outpatient clinics at UF, Shands and the VAMC with the mission to provide the highest level of clinical care. He serves as a mentor for all clinical and laboratory research efforts, as well as mentors faculty and fellows in the division to help UF Health take the next step in becoming an international leader in adult diabetes, metabolism, and obesity. His experience in diabetes prior to UF was in the department of medicine at the University of Texas Health Science Center at San Antonio for more than 15 years. Cusi is the principal investigator of various ongoing clinical translational research projects in obesity, Type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). »More
Dr. Michael Haller began working with Type 1 diabetes during his first year of medical school and has committed his academic career to developing safe and effective therapies for the prevention and reversal of T1D. Dr. Haller works with clinicians and researchers to develop a T1D cure. He has published over 75 manuscripts and book chapters about T1D and is the principal investigator of numerous intervention studies for T1D patients. He has received awards and research grants, including the prestigious Juvenile Diabetes Research Foundation (JDRF) Mary Tyler Moore and S. Robert Levine Excellence in Clinical Research Award, the ADA Cure Award, the Lawson Wilkins Clinical Scholar Award, and the ISPAD Young Investigator Award. Dr. Haller is currently funded by the NIH, JDRF, and the Helmsley Trust to support his work in developing combination therapies for T1D. »More
Dr. Ben Keselowsky is an associate professor in the UF Department of Biomedical Engineering. Dr. Keselowsky’s research interests focus on the use of targeted controlled release systems for directing immune cell function, with application in vaccines for Type 1 diabetes and high throughput screening. He is recognized for his individual contributions to diabetes research and innovation, and serves on the Advisory Board of Journal of Materials Chemistry B, and Editorial Board of Journal of Biomedical Materials Research A. His research is funded by the National Institute of Diabetes and Digestive and Kidney Diseases. »More
Professor Clayton Mathews is the director the Center for Immunology and Transplantation as well as the Immunology Graduate Program at the University of Florida. He is an active member of the UF Diabetes Institute and has held the Sebastian Family Chair for Diabetes Research since 2007. The Mathews lab seeks to improve understanding of the Type 1 diabetes at the molecular interface between immune effectors and β cells by identifying genetic factors that provide resistance to beta cell destruction. »More
Dr. Desmond Schatz has been involved in Type 1 diabetes research since the mid 1980’s and has published over 260 manuscripts, the majority related to the prediction, natural history, genetics, immunopathogenesis and prevention of the disease, as well as the management of children and adolescents with Type 1 diabetes. He is the Principal Investigator (PI) on several JDRF and NIH awards. He is PI on JDRF funded studies aimed at reversing Type 1 diabetes and is currently PI the of the UF Clinical Research Center participating in the NIH-funded TrialNet. He serves as co-PI on a Program Project Grant looking at the immunopathogenesis of Type 1 diabetes, and also serves as co-PI for the NIH-funded international newborn genetic screening (TEDDY) program in North Central Florida. He has served in numerous leadership and scientific capacities for the American Diabetes Association and is the president-elect of the ADA. »More
Dr. Janet Silverstein is the Chief of Pediatric Endocrinology in the College of Medicine, holds varied roles as a diabetes clinician, and has served on several committees including the executive committee of the American Academy of Pediatrics and the Children’s Workgroup of the National Diabetes Education Program. Dr. Silverstein focuses on Type 1 diabetes, Type 2 diabetes, obesity, psychosocial issues in pediatric chronic disease, general endocrinology, lipid disorders, and patient advocacy. She helped develop training and educational materials that can be used in schools across the nation to address the needs of children with Type 1 diabetes. Dr. Silverstein writes the Kids Corner, a monthly column in Diabetes Forecast, a publication for people with diabetes. She has chaired the Council of Youth of the American Diabetes Association and has worked with the ADA to develop standards of care for children with diabetes. »More
Dr. Cherie Stabler joined the department of Biomedical Engineering as an associate professor under the Smart Polymer Nanomedicines Initiative. Her research centers on the engineering of cell-based tissues for the treatment of Type 1 diabetes, specifically the development of novel biomaterials for cellular encapsulation, threedimensional scaffolds, and in situ oxygen and drug release. She has published her work in a broad range of journals, with recent publications in Advanced Healthcare Materials and Proceedings of the National Academy of Science. »More
Since 1982, Dr. William Winter has been involved in a variety of research studies on diabetes and related endocrine disorders. In 1997, he was appointed medical director of the UF Health Pathology Laboratories’ Endocrine Autoantibody Laboratory. Dr. Winter is a diplomate of the American Board of Clinical Chemistry and American Board of Pathology-certified in pediatrics, pediatric endocrinology and chemical pathology. He is also is the principal investigator for the islet cell autoantibody core laboratory for the NIH-funded study, “Type 1 Diabetes TrialNet.” His current research interests include studying the more unusual manifestations of diabetes in children and adolescents, autoantibody testing in Type 1 diabetes, and Type 2 diabetes in pediatric patients. »More
Dr. Chang Qing Xia is an Assistant Professor in the Department of Pathology and completed his graduate education in China and two post-doctoral fellowships before becoming an assistant professor at the University of Florida. He studies Type 1 diabetes and uses dendritic cell vaccines to prevent and reverse T1D. Dr. Xia is a key investigator in several diabetes clinical trials at UF, including nutritional intervention and prevention of T1D as well as dendritic cell immunotherapy. »More
The UF Diabetes Institute unties more than 100 faculty members across campus working to prevent, diagnose, and treat diabetes in the areas of genetics, endocrinology, epidemiology, patient and physician education, health outcomes and policy, behavioral science, rural medicine and more.
UF Health Jacksonville is recognized for its multidisciplinary efforts to improve diabetes tracking, prevention and care in the North Florida region. Physician scientists are working to enhance quality of patients through new research, education and participation in clinical trials.
The UF Health Pathology Laboratories’ Endocrine Autoantibody Laboratory makes autoantibody marker testing available for nearly 20 endocrine-related disorders, including Type 1 diabetes.